BioCentury | Sep 19, 2019
Product Development

Anokion’s autoimmunity platform evolution

When the science suggested the liver, and not the blood, could be the better target tissue for tolerance-inducing autoantigens, Anokion devised a platform around the former. About 18 months after its pivot, the company is...
BioCentury | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

Although Boehringer’s recent spate of deals plug pipeline holes in fibrosis and cancer, a broader survey of the pharma’s partnering activity over the last two years shows it delving into technologies that let it jump...
BioCentury | Apr 27, 2018
Company News

Topas, Boehringer partner for immune tolerance candidates for cancer

Topas Therapeutics GmbH (Hamburg, Germany) partnered with Boehringer Ingelheim GmbH (Ingelheim, Germany) to develop antigen-specific tolerance-generating adjuvant candidates delivered via virus-based vectors. The collaboration will initially focus on cancer. Topas will be responsible for the...
BioCentury | Oct 30, 2017
Company News

Management Tracks: Biohaven, Selecta

Neurology company Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) hired Clifford Bechtold as COO. He was development team leader for genetically defined diseases at Bristol-Myers Squibb Co. (NYSE:BMY). Immunology company Selecta Biosciences Inc. (NASDAQ:SELB) hired John...
BioCentury | Sep 1, 2017
Company News

Lilly backs Topas' liver-specific nanoparticles platform

Topas Therapeutics GmbH (Hamburg, Germany) partnered with Eli Lilly and Co. (NYSE:LLY) to develop therapeutics that induce antigen-specific immune tolerance. The companies will initially focus on undisclosed external antigens thought to be involved in autoimmune...
BioCentury | Aug 22, 2017
Company News

Lilly backs Topas' liver-specific nanoparticles platform

Topas Therapeutics GmbH (Hamburg, Germany) partnered with Eli Lilly and Co. (NYSE:LLY) to develop therapeutics that induce antigen-specific immune tolerance. The companies will initially focus on undisclosed external antigens thought to be involved in autoimmune...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
BioCentury | Dec 1, 2016
Targets & Mechanisms

Not a peripheral story

By sourcing T cells directly from the pancreatic islets of Type I diabetes patients, rather than the standard method of taking blood samples, an academic team has provided an unprecedented view into the molecules that...
BioCentury | May 9, 2016
Emerging Company Profile

Deliver to the liver

Topas Therapeutics GmbH is turning a shortcoming of nanoparticles - difficulty escaping the liver - into an advantage. The company is targeting a subset of liver cells that are among the most tolerizing in the body as...
BioCentury | Mar 28, 2016
Finance

Back in the game

After spending the last few years exiting many of its biotech portfolio companies, Gimv is again putting capital to work in the space. The firm is picking up where it left off with a bet...
Items per page:
1 - 10 of 12
BioCentury | Sep 19, 2019
Product Development

Anokion’s autoimmunity platform evolution

When the science suggested the liver, and not the blood, could be the better target tissue for tolerance-inducing autoantigens, Anokion devised a platform around the former. About 18 months after its pivot, the company is...
BioCentury | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

Although Boehringer’s recent spate of deals plug pipeline holes in fibrosis and cancer, a broader survey of the pharma’s partnering activity over the last two years shows it delving into technologies that let it jump...
BioCentury | Apr 27, 2018
Company News

Topas, Boehringer partner for immune tolerance candidates for cancer

Topas Therapeutics GmbH (Hamburg, Germany) partnered with Boehringer Ingelheim GmbH (Ingelheim, Germany) to develop antigen-specific tolerance-generating adjuvant candidates delivered via virus-based vectors. The collaboration will initially focus on cancer. Topas will be responsible for the...
BioCentury | Oct 30, 2017
Company News

Management Tracks: Biohaven, Selecta

Neurology company Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) hired Clifford Bechtold as COO. He was development team leader for genetically defined diseases at Bristol-Myers Squibb Co. (NYSE:BMY). Immunology company Selecta Biosciences Inc. (NASDAQ:SELB) hired John...
BioCentury | Sep 1, 2017
Company News

Lilly backs Topas' liver-specific nanoparticles platform

Topas Therapeutics GmbH (Hamburg, Germany) partnered with Eli Lilly and Co. (NYSE:LLY) to develop therapeutics that induce antigen-specific immune tolerance. The companies will initially focus on undisclosed external antigens thought to be involved in autoimmune...
BioCentury | Aug 22, 2017
Company News

Lilly backs Topas' liver-specific nanoparticles platform

Topas Therapeutics GmbH (Hamburg, Germany) partnered with Eli Lilly and Co. (NYSE:LLY) to develop therapeutics that induce antigen-specific immune tolerance. The companies will initially focus on undisclosed external antigens thought to be involved in autoimmune...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
BioCentury | Dec 1, 2016
Targets & Mechanisms

Not a peripheral story

By sourcing T cells directly from the pancreatic islets of Type I diabetes patients, rather than the standard method of taking blood samples, an academic team has provided an unprecedented view into the molecules that...
BioCentury | May 9, 2016
Emerging Company Profile

Deliver to the liver

Topas Therapeutics GmbH is turning a shortcoming of nanoparticles - difficulty escaping the liver - into an advantage. The company is targeting a subset of liver cells that are among the most tolerizing in the body as...
BioCentury | Mar 28, 2016
Finance

Back in the game

After spending the last few years exiting many of its biotech portfolio companies, Gimv is again putting capital to work in the space. The firm is picking up where it left off with a bet...
Items per page:
1 - 10 of 12